Member Info for B2HS2L

From 21.12.22 - Yourgene placing RNS:

"Background to and reasons for the Placing

Yourgene is focussed on accelerating the growth within the Group's core offerings of Genomic Services, NIPT, Ranger® Technology and PCR tests. Furthermore, at the start of the current financial year, the Company commenced a cost restructuring exercise to remove approximately £5 million of operational expenditure on an annualised basis in order to realign the Group's cost base to its core strategic focus after the reduction in the UK Government's COVID-19 testing activities earlier in 2022.

Prior to this, significant investment has been made to improve Yourgene's offering, its technology as well as its facilities and business processes. The Directors believe that the benefits from these investments will be realised over the next three years driven, primarily by leveraging Ranger® Technology to build commercial relationships within the NIPT and Oncology markets as well as utilising its improved infrastructure to support obtaining future regulatory approvals.

The Directors believe that Yourgene is now being recognised for its capabilities and expertise, this has been demonstrated through its partnerships with Ambry Genetics and EKF Diagnostics Holdings plc.

As part of the Company's strategic priorities, the Directors intend to complement the core products and services by adding third party portfolios to broaden Yourgene's offering and commercial channels. It is expected that this will improve short-term revenue assurance whilst supporting the development of longer-term routes to market. "

+++

This is the product development info within this RNS.

Unsure if further info may appear within prior YGEN RNS's

I hope Novacyt BoD have decided the what's and when's of improvements achievable with a set amount of Novacyt investment, and are confident they can make that happen.

Rees will spend any and all monies provided by NCYT, in an effort to save his own reputation.

I'd like to see which product development milestones can be achieved with what funds, else we are issuing LR with blank cheque's.

FWIW I think Kaeren's

"Why have you still failed to produce an up to date Website"

is the standout of all the candidate killer questions.

1 They have been Faffing at this for months.

2 It's urgent, - because present site makes it look like Novacyt is being run by amateurs.

3 Income from website is being lost the longer this process takes.

4 Novacyt retains the entire price of the products sold. Not so with the likes of Scientific Laboratory Supplies Ltd

5 It's forward looking. Some other questions are backward looking.

A fair question Wilson.

As regards a killer question, I think they would only stonewall, or answer a different question if they became too uncomfortable when placed on the spot.

You might try asking if future M&A were only likely if it meant the target company was financially distressed.

It took too long for this acquisition, and waiting for the above situation (often times as not), requires the predator to play a waiting game.

The 'Does it indeed need a loan' comment was an indication of how much we know about the companies intentions towards total Yourgene investment.

When the business case was completed prior to their offer, did the BoD intend to throw the kitchen sink at the opportunity Yourgene presented? - Probably not.

+++

'poor comms as an opportunity to add' - Comms are as bad as ever.

For me the need to invest would be after a comprehensive update that left investors feeling trust in BoD actions

and capability had been sufficiently improved, - that just might happen if JW were replaced.

FWIW, If confident in future BoD activities, perhaps buying on the dip could be a suitable strategy.

Agree with the arithmetic HarChris.

But we don't know how much further investment is needed on development / marketing of Yourgene products.

Is that a large or a small sum, and is this due soon or not?

When the business case for purchasing Yourgene was completed, how much was to be spent and when.

What were the deliverables, - we have no visibility of finances for this investment, all we know is it won't need a loan.

(or does it indeed need a loan?).

We read what was provided in the July 3rd RNS, but with Novacyt losses continuing, why should we believe the board

are capable of combining the companies and profiting from selling Yourgene's products?

Shareholders are well overdue an update on this development, they don't want, 'we are only at the beginning of merging the two companies'. We need answers to Who, What, When, How much, Why etc.

You know, - as in the Yourgene plan beyond it's purchase.

This goes right to the heart of why it is important for investors to think about re-electing James Wakefield to the board.

@ RMFatGB

Orderly queue?- more a Piranha feeding frenzy

Bella -

I have tried to find a decent source to identify the meaning of 'first line treatment'. I found this:

https://friendsofcancerresearch.org/glossary-term/standard-care/

"In the context of a clinical trial, a patient receiving treatment at the standard of care will be treated with the same drugs they would receive for their condition were they being treated outside of a clinical trial. In this way, researchers can measure the impact of an experimental drug against that of existing treatment.

Where multiple treatments for a condition exist, guidelines and medical practice often distinguish first-line therapies from second-line therapies (and sometimes third- or more).

The ***First line therapy*** for a given disease is the one that most physicians will prescribe to ***previously untreated patients***, usually due to a combination of high effectiveness and low comparative risk.

If that therapy is ineffective, physicians will move on to a ***second line therapy***.

Because different treatments for the same condition often employ different mechanisms, interact differently with other medications, and cause different side effects, second- or third-line therapies can sometimes benefit patients when first-line therapies cannot. This is one of the reasons it can be helpful to have multiple drugs intended to treat the same disease."

++++

Re - 'P2 will be based on C7 dose administered 2 weekly to include early and late stage STS'

According to the above then, there is no reason why P2 will not include early and late stage STS'.

The dose might be C6 or C7 dosage, as justifying C5 or lower would not seem feasible.

JW sweating on resolution 11.

Resolves to renew Mr. James Wakefield office as member of the Board of Directors of the Company.

Hopefully not enough votes yet.

Hopefully not enough votes by 26.10.23.

Failing to gain re-election to the board will vacate the Chairman's position.

This opportunity only occurs once every three years.

++++

Have just re-voted via HL, as it stated I had not voted for the 26th Oct AGM meeting.

I voted in exactly the same manner.

We can't be worse off with anyone else as Chairman than we are now.

1 https://www.mskcc.org/cancer-care/types/soft-tissue-sarcoma/types#:~:text=Soft%20tissue%20sarcoma%20starting%20in,sarcomas%20of%20the%20connective%20tissue

Title - Types of Soft Tissue Sarcoma

"Soft tissue sarcoma types are determined by the way a sample of cells from the tumour looks under a microscope.

A surgeon will obtain the sample during a biopsy or during surgery to remove the tumour.

There are more than 80 types of soft tissue sarcoma or sarcoma-like growths.

Knowing which type you have helps doctors predict how the tumour will respond to specific treatments."

2 https://clinicalsarcomaresearch.biomedcentral.com/articles/10.1186/s13569-020-00137-5 -

Title - Survival of soft tissue sarcoma patients after completing six cycles of first-line anthracycline containing treatment:

"Background

Soft tissue sarcomas (STS) are a rare group of tumours comprising approximately 1% of all cancers and containing approximately 70 different histological entities.

Clinical behaviour differs between the various histological entities.

Surgery is the primary treatment for localized disease when resection is possible with the option of adding neo-adjuvant or adjuvant radiotherapy.

For patients with locally advanced and/or distant metastatic disease (that is, Cancer that spreads from where it started to a distant part of the body), the goal of treatment is to prolong survival, and treatment mainly consists of systemic treatment, e.g. cytotoxic drugs and tyrosine kinase inhibitors.

The current first line chemotherapy consists of anthracycline based chemotherapy either as monotherapy or combination therapy"

3 RNS 19 Sept.

"...in parallel with the completion of cohort 7, the Company intends to begin a short study to explore more frequent dosing (fortnightly) of AVA6000 AS A FIRST LINE TREATMENT in patients with Soft Tissue Sarcoma.

The study is expected to begin in Q4 2023 subject to receipt of approval of a protocol amendment from the US Food & Drug Administration (FDA)."

+++

After reading references 1 and 2, the following could be true for study participants.

😁 Unless the FDA amended protocol disbars study entry for certain STS sub-types, the amendment will allow patients to receive AVA6000 as a first line treatment for each and every STS sub-type.

😁 On joining the study - metastatic STS patients will have AVA6000 treat multiple solid tumour sites,

and localised disease patients will avoid surgery.

😁 There could possibly be study patients who have an STS tumour that has been deemed inoperable.

AVA6000 would be an attractive option to straight Doxorubicin.

😁 Beyond the study, all participants will still have current standard of care available.

😁 There will be insurance companies who will be pleased a patient has joined the short study, and will not incur the cost of surgery, - at least whilst still on the study.

I hope many STS patients find the study an attractive option in their circumst

My apologies - AVA032 quote from 5th Oct RNS

Thompi - searching the Avacta website

AVA028 combines an Affimer PD-L1 antagonist with IL-2 which is a cytokine that plays a signalling role in expanding the number of activated immune cells (T and NK cells).

++++

AVA032 - our anti-PD-L1 Affimer® fused to the pro-inflammatory cytokine interleukin 15 (IL-15), displays encouraging efficacy when tested in multiple models of immunomodulation, stimulating a potent immune response and reversing the immunosuppressive tumour microenvironment.

Perhaps Mandy should know of your discovery Wilson.

It's for Novacyt to act if HL information is incorrect.

Ditto if they have RNS'd incorrect info.

Good spot though, - well done.

One board member leaving and two arriving could be 5% of what is happening behind the scenes, or 95%.

Nobody is likely know.

It's fishy because TFG have been silent for a very long time,

apparently waiting for board members to come to their senses.

Board changes are what can happen when a large shareholder loses patience with BoD, or hatches a

plan or plans to suite themselves.

I'm not saying it's happening, but TFG may want action a little faster than the board has so far highlited.

JW not up for re-election to the board last year, or the year before.

Or perhaps Dr John Brown, previous Yourgene Chairman.

what happens next, - board deliberate to choose a new chairman.

SP will probably rise in celebration.

JW sweating on resolution 11.

Resolves to renew Mr. James Wakefield office as member of the Board of Directors of the Company.

Hopefully not enough votes yet.

Hopefully not enough votes by 26.10.23.

Failing to gain re-election to the board will vacate the Chairman's position.

This opportunity only occurs once every three years.

Appointment of Chief Medical Officer 3 Oct

Appointment of New Chief Financial Officer 11 Oct

Why are these appointments necessary, - what was wrong with the old CFO?

I'm asking myself if TFG are behind these changes, and whether they have further plans to roll out.

...(e.g., less dose-limiting toxicity for an oncology agent), with evidence of similar efficacy

I feel it's more

no dose-limiting toxicity (as yet) for an oncology agent, with evidence of greater efficacy....!

Muck,

Was viewing this tonight -

Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review - FDA Overviews,

https://www.fda.gov/patients/learn-about-drug-and-device-approvals/fast-track-breakthrough-therapy-accelerated-approval-priority-review

Content current as of: 06/12/2023

I thought it relevant to your post

Https://shop.novacyt.com/

This is the shop website that needs sorting out most I think.

Shop first discovered in July 2023, - BoD are showing it is not a priority.

Four months later and it is still in embrio. Disgraceful, anybody would think we don't need the sales.